| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAM17 |
| Uniprot No | P78536 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 215-671aa |
| 氨基酸序列 | RADPDPMKNTCKLLVVADHRFYRYMGRGEESTTTNYLIELIDRVDDIYRN TSWDNAGFKGYGIQIEQIRILKSPQEVKPGEKHYNMAKSYPNEEKDAWDV KMLLEQFSFDIAEEASKVCLAHLFTYQDFDMGTLGLAYVGSPRANSHGGV CPKAYYSPVGKKNIYLNSGLTSTKNYGKTILTKEADLVTTHELGHNFGAE HDPDGLAECAPNEDQGGKYVMYPIAVSGDHENNKMFSNCSKQSIYKTIES KAQECFQERSNKVCGNSRVDEGEECDPGIMYLNNDTCCNSDCTLKEGVQC SDRNSPCCKNCQFETAQKKCQEAINATCKGVSYCTGNSSECPPPGNAEDD TVCLDLGKCKDGKCIPFCEREQQLESCACNETDNSCKVCCRDLSGRCVPY VDAEQKNLFLRKGKPCTVGFCDMNGKCEKRVQDVIERFWDFIDQLSINTF GKFLADN |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant expression and characterization of the catalytic domain of ADAM17 for structural studies"**
- *Author(s): Smith J, et al.*
- 摘要：研究报道了ADAM17催化结构域的重组表达及纯化方法，通过X射线晶体学解析其三维结构，揭示了底物结合位点的关键氨基酸残基，为靶向抑制剂设计提供结构基础。
2. **"Functional analysis of ADAM17 in TNF-α shedding using a novel recombinant protein system"**
- *Author(s): Lee H, et al.*
- 摘要：构建重组ADAM17蛋白体外模型，验证其剪切TNF-α前体的活性，并发现金属蛋白酶活性依赖锌离子的调控，为炎症性疾病治疗机制研究提供工具。
3. **"Development of a high-yield mammalian cell system for producing active ADAM17 ectodomain"**
- *Author(s): Müller SA, et al.*
- 摘要：优化哺乳动物细胞表达系统，实现ADAM17胞外域的高效分泌表达，蛋白经糖基化修饰后具有天然活性，适用于药物筛选及功能研究。
4. **"ADAM17 protease inhibitors designed based on recombinant protein-substrate interaction analysis"**
- *Author(s): Zhang R, et al.*
- 摘要：利用重组ADAM17蛋白与荧光标记底物的结合实验，筛选出小分子抑制剂，并通过体外实验验证其抑制肿瘤细胞迁移的效应，推动抗癌药物开发。
(注：以上文献信息为示例性概括，实际引用需查询具体论文。)
ADAM17 (A Disintegrin and Metalloproteinase 17), also known as TNF-α-converting enzyme (TACE), is a membrane-anchored protease belonging to the ADAM family. First identified in the 1990s, it gained prominence for its role in cleaving membrane-bound tumor necrosis factor-alpha (TNF-α), releasing the soluble cytokine critical in inflammatory and immune responses. Structurally, ADAM17 comprises a prodomain, catalytic metalloproteinase domain, disintegrin-cysteine-rich region, transmembrane domain, and cytoplasmic tail. This multidomain architecture enables its involvement in ectodomain shedding, a process regulating cell signaling by releasing soluble forms of over 80 substrates, including growth factors (e.g., EGFR ligands), adhesion molecules, and cytokine receptors.
Beyond TNF-α, ADAM17 modulates pathways like EGFR signaling, Notch activation, and IL-6 receptor shedding, impacting inflammation, tissue development, and cancer progression. Its dysregulation is linked to diseases such as rheumatoid arthritis, inflammatory bowel disease, Alzheimer’s, and multiple cancers (e.g., colorectal, breast), where overexpression correlates with poor prognosis. Pharmaceutical targeting of ADAM17 has been explored, though early inhibitors faced challenges due to off-target effects on related metalloproteases like ADAM10.
Recombinant ADAM17 proteins, typically produced in mammalian or insect cell systems, retain enzymatic activity for structural studies, inhibitor screening, and mechanistic research. These purified proteins enable in vitro analysis of substrate specificity, regulatory mechanisms (e.g., phosphorylation, oxidative activation), and interactions with TIMP3 (a natural inhibitor). Despite therapeutic hurdles, recombinant ADAM17 remains vital for dissecting its biological roles and developing selective modulators for precision medicine applications.
×
